DAI-NIPPON-PRINTING
16.12.2020 07:08:08 CET | Business Wire | Press release
Amid increased awareness of hygiene and safety as the Covid-19 pandemic continues to spread around the world, Dai Nippon Printing Co., Ltd. (DNP) (TOKYO: 7912) has developed a new transparent display screen that can be operated in a touchless format, by merely moving a hand over a motion sensor. By removing the need to make direct contact with the cursor, the newly developed screen will be positioned as a countermeasure to the spread of Covid-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215006213/en/
https://www.youtube.com/watch?v=h5QKhThRtWw
A liquid crystal (LC) light control film is attached to a transparent screen facilitating a variety of video expressions on a single screen, from standard displays to augmented reality (AR) driven effects, including those where vivid images appear to hang in the air.
For further information about LC light control film, please visit:
https://www.dnp.co.jp/eng/news/detail/1191596_2453.html
For further information about transparent screens that can be used in bright location please visit:
https://www.dnp.co.jp/eng/news/detail/10158931_2453.html
.
[Background]
As health and safety awareness grows, more users are calling for the development of products with antibacterial and antiviral functions, along with those that can be used in a touchless format.
At the same time, we have also recently seen a heightened focus on AR technology that supports consumer activities by imposing artificially created information over existing real world information. In answer to these dual developments, DNP has created a touchless display screen capable of giving expression to AR-driven spatial effects that enhance the immersive impact of presentations.
This has been achieved through the successful combination of, 1, a motion sensor that detects the operator’s movements, 2, an LC light control film that produces a clear image, and 3, a transparent screen that heightens the AR effect.
[Display Features]
- The in-built motion sensor detects the movements of users and operators, and by activating the LC light control film, which is integrated into the transparent screen, makes it possible to display clearer images.
- Bringing the palm of the hand closer to the screen activates the sensor, which causes the cursor to appear. The cursor can then be maneuvered in a touchless format via hand movements, including clicking on screen buttons to set actions into motion by bending the index finger towards the screen.
- DNP’s proprietary LC light control film leverages coating technology to achieve a precise coating of the LC. And, by controlling the direction of the LC using electrical power, it is possible to block or transmit light with high precision, enabling the display of diverse and clear images.
- The DNP transparent screen is produced by applying a precision lens to a large film substrate using advanced optical lens design technology and fine shaping technology.
- The background can be viewed by making the integrated LC light control film transparent then projecting an image upon it. In this way, it is possible to achieve an AR effect in which images appear to hand in the air.
[Looking Ahead]
We anticipate a variety of usage scenarios for the touchless transparent screen, such as in vending and ticket machines, along with uses as the reception desks at hotels and companies. In addition, DNP will further develop and propose LC light control films and transparent screens targeting touchless displays as a countermeasure against infectious diseases.
[About DNP]
DNP is one of the world’s largest comprehensive printing companies, providing a diverse portfolio of products and services to about 20,000 corporate clients worldwide. Since we were founded in 1876, we have consistently innovated new products and processes, and have successfully integrated proprietary printing and information technologies to branch out into various fields, including packaging, decorative materials, display components, and electronic devices. DNP continues to take on the challenge of new business fields, including those related to the environment, energy, and life sciences. Our aim is to become a principal provider of solutions to a variety of problems by developing and combining new technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215006213/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
